The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi
At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor [...]
Predicting the Long-Term Survival of Men with A Biochemical Recurrence Post-Surgery Who Are Hormone Naive Can Change How We Treat Them
Appearing in the European Journal of Nuclear Medicine and Molecular Imaging a recent study provides data on the long-term survival of men with a biochemical recurrence after failed surgery. In the study by Giovacchini et [...]
Is Delaying The Start of ADT Safe for Prostate Cancer Patients?
A recently previewed (prior to the upcoming ASCO Annual Meeting) of a large study shows that men with prostate cancer who had a PSA-based relapse (Biochemical Recurrence) could delay starting androgen deprivation therapy (ADT) until [...]
Cardiovascular Disease And Its Relationship With Androgen Deprivation (ADT)
Clinicians believe that there is an association between the risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer. Researchers took data from 2006 to 2012 on filled [...]
Is Advanced Prostate Cancer Changing? The Evolution of Metastatic Castrate Resistant Prostate Cancer And The Need To Make Some Research Changes
Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). [...]
Predicting Who Will Have A Positive Result From Abiraterone (Zytiga) In Men With Metastatic Castrate Resistant Prostate Cancer
We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a [...]